MedTrace Logo

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

NCT00225082 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2010-10-05

No results posted yet for this study

Summary

HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir treatment and after 4.

Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and mitochondrial function at 48 weeks.

Conditions

  • HIV Infection

Interventions

DRUG

Nucleoside analogue switch

stavudine switched to tenofovir

Sponsors & Collaborators

Principal Investigators

  • Robert L Murphy, MD · Northwestern University

  • Mariana Gerschenson, Ph.D. · University of Hawaii

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2006-12-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00225082 on ClinicalTrials.gov